Continuous Intravenous Nimodipine Infusion With Ethanol as Carrier in Aneurysmal Subarachnoid Hemorrhage Does Not Result in Measurable Cerebral Ethanol Levels
Clinical Pharmacology & Therapeutics · 2025
DOI: 10.1002/cpt.3753 ↗At a glance
Journal article in Clinical Pharmacology & Therapeutics, 2025. Written by Miriam M Moser and 8 co-authors. Institution: Department of Neurosurgery, Medical University of Vienna, Vienna, Austria. Major MEDLINE topics: Nimodipine, Subarachnoid Hemorrhage, Ethanol, Brain. 32 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
An unimpaired neurological evaluation is essential for detecting delayed cerebral ischemia (DCI) in aneurysmal subarachnoid hemorrhage (aSAH) patients. Nimodipine is currently the only drug approved for DCI prevention. Intravenous nimodipine infusion contains 23.7 vol% ethanol as an excipient, resulting in up to 45 g of ethanol being infused daily, which may interfere with neurological assessment. Therefore, we aimed to measure ethanol concentrations in plasma, cerebrospinal fluid (CSF), and brain parenchyma during the infusion of 0.5–2 mg of nimodipine per hour in aSAH patients to quantify the ethanol neuronal exposure. Ethanol concentrations were determined by headspace gas chromatography‐flame ionization detection in plasma and CSF and we set out brain parenchyma measurement using cerebral microdialysis, in 10 aSAH patients. In each compartment four samples were taken over a 6‐hour interval during steady‐state intravenous nimodipine infusion at four different doses (0.5, 1, 1.5 and 2 mg/hour). A total of 307 samples from plasma and CSF was measured. Ethanol levels were mostly below the quantification limit of 0.002 g/100 mL. In 36 samples ethanol concentration was ≥ 0.002 g/100 mL, ranging from 0.002 to 0.009 g/100 mL. These low values were not reproducible in a second measurement, suggesting these values likely reflected analytical variability rather than true ethanol concentrations. Nimodipine analysis in brain parenchyma was omitted due to insufficient microdialysate volume and low concentrations in blood and CSF. Continuous nimodipine infusion of up to 2 mg/hour is unlikely to impair neurological assessment in aSAH patients, as no significant CSF ethanol concentration (< 0.002 g/100 mL) was detected.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Neurosurgery, Medical University of Vienna, Vienna, Austria.
- Department of Anesthesia, General Intensive Care Medicine and Pain Management, Medical University of Vienna, Vienna, Austria.
- Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
ORCID profiles: Miriam M Moser, Karl Rössler, Dorian Hirschmann, Walter Plöchl, Johannes Herta, Andrea Reinprecht, Markus Zeitlinger, Arthur Hosmann
Cite
APA
Moser, M. M., Rössler, K., Hirschmann, D., Gramss, L., Plöchl, W., Herta, J., Reinprecht, A., Zeitlinger, M., & Hosmann, A. (2025). Continuous Intravenous Nimodipine Infusion With Ethanol as Carrier in Aneurysmal Subarachnoid Hemorrhage Does Not Result in Measurable Cerebral Ethanol Levels. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3753
Vancouver
Moser MM, Rössler K, Hirschmann D, Gramss L, Plöchl W, Herta J, et al. Continuous Intravenous Nimodipine Infusion With Ethanol as Carrier in Aneurysmal Subarachnoid Hemorrhage Does Not Result in Measurable Cerebral Ethanol Levels. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3753
BibTeX
@article{Moser2025,
author = {Moser, Miriam M and Rössler, Karl and Hirschmann, Dorian and Gramss, Leon and Plöchl, Walter and Herta, Johannes and Reinprecht, Andrea and Zeitlinger, Markus and Hosmann, Arthur},
title = {Continuous Intravenous Nimodipine Infusion With Ethanol as Carrier in Aneurysmal Subarachnoid Hemorrhage Does Not Result in Measurable Cerebral Ethanol Levels},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
doi = {10.1002/cpt.3753}
}
EUVIMED